The Short Version
The claim is accurate on its own terms. Multiple independent research groups have reported newly developed compounds — including GL-II-73, P7C3-A20, NU-9, and FLAV-27 — that reversed cognitive deficits in rodent models of Alzheimer's disease. However, the claim omits critical context: animal models are widely recognized as poor proxies for human Alzheimer's, no such reversal has been demonstrated in humans, and the history of translating preclinical AD successes to clinical benefit is marked by repeated failure.